Counterfeit Products, Dosing Errors, Illegal Online Sales, and Quality Failures in the Compounded GLP-1 Market
Source: FDA Drug Safety Communications | Data as of June 26, 2026 | Read time: ~9 min
The U.S. Food and Drug Administration has issued a comprehensive warning about the risks posed by unapproved, compounded, and counterfeit versions of GLP-1 medications — including semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). The agency’s concerns span a wide range of overlapping problems. These problems include products containing unapproved salt forms of the active drug, dosing errors that have resulted in hospitalizations, fraudulent labels naming pharmacies that never compounded the product, cold-chain failures during shipping, illegal online pharmacies, and outright counterfeit medications marketed as genuine branded products.
The FDA’s position is unambiguous. Unapproved compounded GLP-1 drugs do not undergo the agency’s review for safety, effectiveness, or quality before they are marketed. That is not a minor procedural distinction. It means that patients using compounded semaglutide or tirzepatide products are, in effect, taking a medication whose safety profile has not been independently verified at the level required of any drug sold in the United States under FDA approval. The risks documented on this page are the practical consequences of that verification gap.
The agency’s full guidance is published at FDA’s drug safety communications page. The details below are drawn directly from that source.
Why Patients Turned to Compounded GLP-1 Drugs — and Why the FDA Is Concerned
The demand for compounded GLP-1 products emerged primarily during the period when FDA-approved semaglutide and tirzepatide were in nationwide shortage. When a drug is on the FDA shortage list, certain compounding activities that would otherwise be restricted become temporarily permissible under federal law. That legal opening, combined with the high list prices of branded GLP-1 products and the rapid growth of telehealth platforms capable of distributing prescriptions and products at scale, created the conditions for a compounded GLP-1 market that grew faster than any regulator could easily monitor. The legal and safety dimensions of that market are covered in detail in the compounded GLP-1 medications coverage on this site.
The FDA’s concern is not with all compounding. Compounded drugs serve a legitimate and important function in healthcare: a patient with an allergy to an inactive ingredient in an approved product, or a clinical need for a dose or formulation not commercially available, has a genuine medical reason to use a compounded version. The problem the agency has identified is something different — the mass-scale marketing of compounded GLP-1 products as direct substitutes for FDA-approved drugs, often to patients who could access the branded product but prefer a cheaper or more convenient alternative. The FDA has been explicit that compounded drugs are not intended to serve as lower-cost copies of commercially available medications.
Red Flags the FDA Wants Patients to Recognize
The agency has published specific warning signs that consumers should treat as grounds for serious concern when dealing with any online pharmacy or telehealth platform offering GLP-1 medications. These are not abstract risks — each of the following patterns has been identified in real products and companies the FDA has already taken action against. A platform or product raises serious red flags if it:
- Claims the compounded drug is the same as or equivalent to an FDA-approved product
- Offers prices that are dramatically lower than the branded medication, to a degree that suggests the product may not be what it claims
- Ships medication that looks different from the branded product or from previous orders, or that arrives in damaged packaging without instructions for use
- Does not require a proper medical screening and licensed physician prescription before dispensing
- Has no licensed physician available to answer questions after the medication has been received
- Has spelling errors on the label, incorrect pharmacy addresses, or other signs of fraudulent documentation
- Includes a pharmacy name on the label that cannot be verified as a licensed, operational compounding pharmacy
The FDA’s BeSafeRx campaign provides additional resources for safely purchasing prescription medications online, including a pharmacy verification tool.
Retatrutide and Cagrilintide: Two Compounds That Cannot Legally Be Used
The FDA has made clear that two specific investigational drugs — retatrutide and cagrilintide — cannot be lawfully used in compounding under federal law. These are not drugs that are in shortage or commercially unavailable in an alternative form; they are drugs that have not been approved for any use in humans and have not been found safe or effective. Neither is a component of any FDA-approved product. Compounding pharmacies, outsourcing facilities, and API distributors are prohibited from producing, supplying, or repackaging them, full stop.
Despite this, the FDA has issued formal warnings to all three types of entities:
- Telehealth companies marketing unapproved drugs including retatrutide, in some cases directly to consumers through digital advertising
- Active pharmaceutical ingredient distributors for selling retatrutide and other GLP-1 APIs to compounders who lacked lawful authority to receive them
- Outsourcing facilities that repackaged retatrutide in violation of federal compounding law
Patients who have been offered or prescribed retatrutide or cagrilintide outside of a registered clinical trial should understand that they are being offered a product with no established safety or efficacy record and no lawful basis for commercial use.
Refrigeration Failures: When Temperature Compromise Affects Drug Quality
Injectable GLP-1 medications — both FDA-approved and compounded — require refrigeration as specified in their package inserts. The drug’s molecular stability depends on maintaining the cold chain from manufacturer through pharmacy through delivery to the patient’s home. When that chain is broken, the product that arrives at the patient’s door may have been degraded in ways that are not detectable by physical inspection.
The FDA has received multiple complaints that compounded GLP-1 drugs have arrived warm, with inadequate ice packs, or with packaging that provided insufficient thermal protection to maintain the required storage temperature during transit. The agency’s recommendation is direct: any injectable GLP-1 drug — compounded or branded — that arrives warm or without adequate refrigeration should not be used. Temperature compromise can alter the drug’s potency, stability, and safety profile in ways that are not visible and that may produce unpredictable clinical effects.
Do not use any injectable GLP-1 medication that arrives at room temperature, warm to the touch, or without adequate ice packs. Contact the pharmacy and your prescriber immediately. This applies to both compounded and branded products.
Import Enforcement: The FDA’s Green List Alert
As a complement to its domestic enforcement activity, the FDA has established a Green List Import Alert (66-80) specifically targeting GLP-1 active pharmaceutical ingredients (APIs) with potential quality concerns. Under this alert, FDA personnel at ports of entry are authorized to detain GLP-1 APIs from manufacturers that have not been verified as compliant with the agency’s good manufacturing practice standards.
The alert is not a blanket ban on all imported GLP-1 APIs. Manufacturers that have undergone an FDA inspection or other formal compliance evaluation and have been found to meet the agency’s manufacturing standards continue to be able to import GLP-1 APIs lawfully. What the alert targets are APIs from manufacturers whose quality controls have not been verified — and whose products, if they enter the compounding supply chain, may produce drugs of unknown purity, potency, or sterility.
This border control mechanism addresses a specific and documented risk pathway: foreign-made APIs of uncertain quality entering the U.S. through unlicensed or unverified channels, being incorporated into compounded GLP-1 products, and ultimately reaching patients who have no way of knowing the origin or quality of what they are injecting.
Counterfeit Ozempic and Fraudulent Compounded Products
Beyond the quality concerns that apply to legitimately produced compounded GLP-1 drugs, the FDA has documented the existence of outright counterfeit and fraudulent products circulating in the market. These are categorically different in risk from regulated compounded products, and the distinction matters for patients trying to understand what they may have received.
Counterfeit Ozempic
The FDA is aware of counterfeit Ozempic being marketed in the United States — products that are packaged and labeled to appear identical to genuine Novo Nordisk product but that may contain wrong ingredients, no active ingredient, too much or too little of an active substance, or other harmful materials. Counterfeit drugs are illegal and dangerous. The FDA investigates reports of suspected counterfeits to assess the public health risk and determine the appropriate enforcement response, and has stated that it remains vigilant in protecting the drug supply from these threats.
Fraudulent Labels and Phantom Pharmacies
A particularly troubling variant involves compounded products whose labels name pharmacies that either do not exist or that, based on information the FDA has gathered, did not actually compound the product in question. In some cases, the FDA has found that a real, licensed pharmacy’s name and information was placed on products that pharmacy had no knowledge of and never produced. The FDA has received at least one documented adverse event report — involving injection site redness, swelling, pain, and a red lump — associated with a product labeled as compounded tirzepatide from a pharmacy that did not compound it.
If you have received a compounded GLP-1 product, verify the compounding pharmacy is licensed and operational in your state. A licensed pharmacy should be contactable, verifiable through your state pharmacy board, and able to confirm it produced your specific lot.
Dosing Errors: Hospitalizations From Compounded Semaglutide and Tirzepatide
One of the most practically significant risks the FDA has identified is not about the product’s composition — it is about how the product is administered. FDA-approved GLP-1 medications like Ozempic and Wegovy are supplied as pre-filled, single-use pen injectors with fixed, pre-loaded doses. Compounded GLP-1 products are typically supplied as multi-dose vials from which patients draw up and measure their own doses using syringes. That delivery difference creates a meaningful error window.
The FDA has received multiple adverse event reports, some requiring hospitalization, from patients who made dosing errors with compounded injectable semaglutide. The errors arose in two main patterns: patients measuring and self-administering incorrect doses due to confusion about the product’s concentration, and healthcare professionals miscalculating doses when prescribing or instructing patients. In either case, the result was incorrect exposure — in some cases overdose — to a pharmacologically potent medication.
Beyond measurement errors, the FDA has also received reports of patients being prescribed compounded semaglutide or tirzepatide at doses, frequencies, or titration schedules that exceed what is described in the FDA-approved drug label. Patients prescribed more product per dose, dosed more frequently, or escalated more rapidly than established protocols specify have reported serious adverse events. The reported effects include nausea, vomiting, diarrhea, abdominal pain, and constipation severe enough to prompt patients to seek medical attention.
Healthcare providers prescribing compounded GLP-1 products should exercise particular care in establishing appropriate starting doses, titration schedules, and patient instructions for measuring and self-administering the medication. Patients should ask their prescriber or pharmacist for explicit, written guidance on measurement before attempting to administer any multi-dose vial GLP-1 product at home.
Semaglutide Salt Forms: A Different Active Ingredient
A specific and technically important concern the FDA has raised involves the chemical form of semaglutide being used in some compounded products. The active ingredient in FDA-approved semaglutide products — Ozempic, Wegovy, and Rybelsus — is semaglutide in its base form. Some compounders have been producing products using salt forms of the molecule — semaglutide sodium or semaglutide acetate — which are chemically distinct from the active ingredient in the approved drugs.
The FDA has been unambiguous on this point: it does not have information establishing that these salt forms have the same chemical and pharmacological properties as the approved active ingredient, and it is not aware of any lawful basis for their use in compounding. Using a salt form of semaglutide is not the same as compounding semaglutide — it is using a different chemical entity for which no regulatory finding of safety or efficacy exists. Patients who have been prescribed or received compounded semaglutide should ask their pharmacy specifically which form of the active ingredient was used.
FDA Adverse Event Data: What the Reports Show
The FDA’s adverse event reporting system has accumulated a substantial number of reports linked to compounded GLP-1 products. As of May 31, 2026, the agency has received:
- 990 adverse event reports associated with compounded semaglutide
- More than 730 adverse event reports associated with compounded tirzepatide
The FDA acknowledges an important limitation in these figures: state-licensed pharmacies that are not registered outsourcing facilities are not legally required to report adverse events to the FDA. The actual number of adverse events occurring in patients using compounded GLP-1 products is therefore likely to be substantially higher than the reported totals. Many of the reported events appear to be consistent with adverse effects associated with the FDA-approved versions of these drugs. However, the compounded products carry additional risks specific to their manufacturing, quality control, dosing, and storage that the approved products do not share to the same degree.
The broader adverse event profile of GLP-1 drugs — including the serious gastrointestinal injuries that form the basis of thousands of personal injury lawsuits currently pending in federal court — is documented extensively across this site. Those claims primarily involve FDA-approved products, and the GLP-1 litigation is one of the largest pharmaceutical mass tort proceedings in American history.
Products Sold Online and Products Falsely Labeled “For Research Only”
The FDA’s enforcement challenges extend beyond traditional pharmacy channels. The agency actively monitors the internet for fraudulent or unapproved drugs and has issued warning letters to companies illegally marketing semaglutide and tirzepatide through online channels. These products may be counterfeit, may contain wrong or harmful ingredients, or may contain too little, too much, or none of the active ingredient at all. The agency urges consumers to purchase prescription medications only from state-licensed pharmacies.
A particularly dangerous category involves drugs labeled “for research purposes only” or “not for human consumption.” These designations have been used by companies to attempt to circumvent the regulatory requirements that apply to drugs intended for human use. In practice, these products have been sold directly to consumers with dosing instructions, making the labeling a legal fiction rather than an accurate description of how the product is being sold and used. The FDA has issued formal warnings to companies marketing unapproved drugs containing semaglutide, tirzepatide, and retatrutide under these misleading labels, and the agency urges consumers not to purchase them. The quality of these products is unknown and they may be harmful.
Never purchase or use any product labeled “for research use only” or “not for human consumption” as a weight-loss drug. These labels are not a safety guarantee — they are a signal that the product has not been reviewed for safety or effectiveness by any regulatory authority.
What Patients Should Do
The FDA’s guidance for patients is grounded in a practical risk-reduction framework rather than a blanket prohibition on compounded products. For patients considering or currently using a compounded GLP-1 medication, the following steps are consistent with the agency’s recommendations:
Obtain a prescription from a licensed physician and fill it at a state-licensed, verifiable pharmacy. The FDA’s BeSafeRx resources can help patients check whether an online pharmacy is legitimately licensed.
- Verify that your pharmacy is licensed and in good standing with your state pharmacy board — a straightforward search on your state board’s website should confirm this
- Ask your pharmacy directly which form of the active ingredient is being used, and whether the product was compounded in-house or sourced from a third party
- Do not use any injectable product that arrives at room temperature or with inadequate cold packaging — contact the pharmacy immediately
- Request explicit written instructions on how to measure and administer your dose before attempting to use a multi-dose vial at home
- If you are being prescribed doses, frequency, or dose escalation schedules that seem more aggressive than what is described in the branded product’s labeling, discuss this with your prescriber
- Never purchase GLP-1 medications from websites without verifying they are a licensed pharmacy, and never use products labeled for research purposes
If you have experienced adverse effects from a compounded GLP-1 product, report them to the FDA through MedWatch, and inform both your prescriber and the compounding pharmacy. Even if adverse event reporting is not legally required of all compounders, the more data the agency receives, the better equipped it is to identify patterns and take protective action.
Key Takeaways
The FDA’s concerns about unapproved and compounded GLP-1 products are specific, documented, and serious. For anyone who has used, is considering, or has been harmed by a compounded or counterfeit GLP-1 medication, the core points to carry from this page are:
- Compounded GLP-1 drugs are not FDA-approved and have not been reviewed for safety, effectiveness, or quality
- The FDA has documented dosing errors causing hospitalizations, refrigeration failures, fraudulent labels, counterfeit branded products, and the illegal marketing of unapproved compounds including retatrutide and cagrilintide
- Some compounded products have used semaglutide salt forms — chemically different from the approved active ingredient — with no established safety data
- As of May 31, 2026, the FDA has received 990 adverse event reports from compounded semaglutide and over 730 from compounded tirzepatide, with the true number likely substantially higher due to underreporting
- Products labeled “for research only” or “not for human consumption” are not a safe or legal source of GLP-1 therapy
- Patients should obtain prescriptions from licensed physicians, fill them at verified state-licensed pharmacies, and reject any product that arrives warm or with inadequate cold packaging
Source: FDA Drug Safety Communication: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Disclaimer: The information provided on this page is intended for general informational purposes only and does not constitute medical or legal advice. The regulatory guidance and safety data referenced herein are drawn directly from the U.S. Food and Drug Administration’s public communications. Patients should consult a licensed healthcare provider before making any changes to their medications. If you or a loved one has suffered injuries potentially related to a compounded or FDA-approved GLP-1 medication, consult a qualified attorney to discuss your legal options.